2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.09 Survival Outcomes of Lung Adenocarcinoma with Intestinal Differentiation in the Era of Immunotherapy

Pdf Summary

The study, conducted by researchers from the Fred Hutchinson Cancer Center and the University of Washington, investigates survival outcomes of lung adenocarcinoma with intestinal differentiation (LAID) in the context of evolving immunotherapy treatments. The analysis includes data from 855 LAID cases and 39,661 non-idiopathic lung adenocarcinoma (LUAD) cases. <br /><br />Key demographic characteristics revealed no significant differences between LAID and LUAD groups regarding age, gender, and insurance status. However, treatment differences were observed. A higher proportion of LAID patients (45%) received chemotherapy alone compared to LUAD patients, whereas 48% of LAID patients and 42% of LUAD patients received combined chemo-immunotherapy treatments. The study also revealed a minority of LAID patients (7.5%) were treated with immunotherapy alone.<br /><br />The survival analyses found notable differences in the efficacy of treatment approaches. Mucinous, enteric, and colloid subtypes within LAID showed varying survival outcomes, emphasizing the heterogeneity within this cancer category. The survival probability over 60 months highlights the improved outcomes associated with integrating immunotherapy, yet there is variation based on specific histological subtypes.<br /><br />In terms of comorbid conditions and socioeconomic factors, the study reported comparable comorbidity rates and income quartile distributions between both disease groups. It noted a small proportion of the patient population coming from community treatment facilities, emphasizing a more significant proportion from academic or integrated health centers, although this did not significantly impact treatment outcomes.<br /><br />Overall, the study underscores the importance of personalized treatment regimens that consider the specific histological differentiation and treatment history of lung adenocarcinoma patients, while also highlighting the role of immunotherapy in potentially improving survival outcomes. Further investigation into tailored therapeutic strategies could help optimize care for LAID patients in the immunotherapy era.

Asset Subtitle

Micah Tratt

Meta Tag

Speaker Micah Tratt

Topic Metastatic NSCLC – Immunotherapy

Keywords

lung adenocarcinoma

immunotherapy

intestinal differentiation

survival outcomes

chemotherapy

histological subtypes

personalized treatment

Fred Hutchinson Cancer Center

University of Washington

therapeutic strategies